Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2022-03-31 00:00:00 ET · period of report 2022-03-29 · accession 0000899243-22-012989 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-31 | 2022-03-29 | ANTX | Easom Eric | CEO, Dir | C - Cnv Deriv | — | +4,907 | 4,907 | New | — |
| D | 2022-03-31 | 2022-03-29 | ANTX | Easom Eric | CEO, Dir | C - Cnv Deriv | $0.00 | -4,907 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-29 | C | A | 4,907 | — | 4,907 | D | — | — | (F1) Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. |
| 2 | Derivative | Series A Convertible Preferred Stock | 2022-03-29 | C | D | 4,907 | $0.00 | 0 | D | — · — to — | 4,907 Common Stock | (F1) Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. |